Company intelligence / Profile preview
PharmaDrug Inc.
Toronto, Ontario, Canadapharmadrug.ca ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
PharmaDrug’s lead asset PD‑001 has completed stability studies supporting manufacturing for clinical trials. The company has initiated start-up activities for its first human clinical study targeting viral infectious diseases. Sairiyo Therapeutics received FDA orphan drug designation for cepharanthine in esophageal cancer.
- Therapeutic areas
- OtherOncologyNeurologyInfectious Diseases
- Modalities
- Reformulated natural products (e.g., cepharanthine)Synthetic formulations of existing drugsPsychedelics and controlled substancesCannabis-derived medicinesFunctional mushrooms/natural-based medicines
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on PharmaDrug Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PharmaDrug Inc..